6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
commonly O
observed O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
incidence O
of O
placebo O
patients O
) O
are O
: O
insomnia O
, O
ejaculation O
disorder O
( O
primarily O
ejaculatory O
delay O
) O
, O
nausea O
, O
sweating O
increased O
, O
fatigue O
and O
somnolence O
, O
decreased O
libido O
, O
and O
anorgasmia O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Allergan O
at O
1-800- O
433-8871 O
, O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Clinical O
Trial O
Data O
Sources O
Pediatrics O
( O
6 O
-17 O
years O
) O
Adverse O
events O
were O
collected O
in O
576 O
pediatric O
patients O
( O
286 O
Lexapro O
, O
290 O
placebo O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
in O
double-blind O
placebo-controlled O
studies O
. O

Safety O
and O
effectiveness O
of O
Lexapro O
in O
pediatric O
patients O
less O
than O
12 O
years O
of O
age O
has O
not O
been O
established O
. O

Adults O
Adverse O
events O
information O
for O
Lexapro O
was O
collected O
from O
715 O
patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
who O
were O
exposed O
to O
escitalopram O
and O
from O
592 O
patients O
who O
were O
exposed O
to O
placebo O
in O
double-blind O
, O
placebo-controlled O
trials O
. O

An O
additional O
284 O
patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
were O
newly O
exposed O
to O
escitalopram O
in O
open-label O
trials O
. O

The O
adverse O
event O
information O
for O
Lexapro O
in O
patients O
with O
GAD B-Not_AE_Candidate
was O
collected O
from O
429 O
patients O
exposed O
to O
escitalopram O
and O
from O
427 O
patients O
exposed O
to O
placebo O
in O
double-blind O
, O
placebo-controlled O
trials O
. O

Adverse O
events O
during O
exposure O
were O
obtained O
primarily O
by O
general O
inquiry O
and O
recorded O
by O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
without O
first O
grouping O
similar O
types O
of O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

In O
the O
tables O
and O
tabulations O
that O
follow O
, O
standard O
World O
Health O
Organization O
( O
WHO O
) O
terminology O
has O
been O
used O
to O
classify O
reported O
adverse O
events O
. O

The O
stated O
frequencies O
of O
adverse O
reactions O
represent O
the O
proportion O
of O
individuals O
who O
experienced O
, O
at O
least O
once O
, O
a O
treatment-emergent O
adverse O
event O
of O
the O
type O
listed O
. O

An O
event O
was O
considered O
treatment-emergent O
if O
it O
occurred O
for O
the O
first O
time O
or O
worsened O
while O
receiving O
therapy O
following O
baseline O
evaluation O
. O

Adverse O
Events O
Associated O
with O
Discontinuation O
of O
Treatment O
Major B-Not_AE_Candidate
Depressive I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
Pediatrics O
( O
6 O
-17 O
years O
) O
Adverse O
events O
were O
associated O
with O
discontinuation O
of O
3.5 O
% O
of O
286 O
patients O
receiving O
Lexapro O
and O
1 O
% O
of O
290 O
patients O
receiving O
placebo O
. O

The O
most O
common O
adverse O
event O
( O
incidence O
at O
least O
1 O
% O
for O
Lexapro O
and O
greater O
than O
placebo O
) O
associated O
with O
discontinuation O
was O
insomnia B-OSE_Labeled_AE
( O
1 O
% O
Lexapro O
, O
0 O
% O
placebo O
) O
. O

Adults O
Among O
the O
715 O
depressed B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
in O
placebo-controlled O
trials O
, O
6 O
% O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
as O
compared O
to O
2 O
% O
of O
592 O
patients O
receiving O
placebo O
. O

In O
two O
fixed-dose O
studies O
, O
the O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
receiving O
10 O
mg/day O
Lexapro O
was O
not O
significantly O
different O
from O
the O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
receiving O
placebo O
. O

The O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
assigned O
to O
a O
fixed O
dose O
of O
20 O
mg/day O
Lexapro O
was O
10 O
% O
, O
which O
was O
significantly O
different O
from O
the O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
receiving O
10 O
mg/day O
Lexapro O
( O
4 O
% O
) O
and O
placebo O
( O
3 O
% O
) O
. O

Adverse O
events O
that O
were O
associated O
with O
the O
discontinuation O
of O
at O
least O
1 O
% O
of O
patients O
treated O
with O
Lexapro O
, O
and O
for O
which O
the O
rate O
was O
at O
least O
twice O
that O
of O
placebo O
, O
were O
nausea B-OSE_Labeled_AE
( O
2 O
% O
) O
and O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
2 O
% O
of O
male O
patients O
) O
. O

Generalized B-Not_AE_Candidate
Anxiety I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
Adults O
Among O
the O
429 O
GAD B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
10-20 O
mg/day O
in O
placebo-controlled O
trials O
, O
8 O
% O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
as O
compared O
to O
4 O
% O
of O
427 O
patients O
receiving O
placebo O
. O

Adverse O
events O
that O
were O
associated O
with O
the O
discontinuation O
of O
at O
least O
1 O
% O
of O
patients O
treated O
with O
Lexapro O
, O
and O
for O
which O
the O
rate O
was O
at O
least O
twice O
the O
placebo O
rate O
, O
were O
nausea B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
fatigue B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Incidence O
of O
Adverse O
Reactions O
in O
Placebo-Controlled O
Clinical O
Trials O
Major B-Not_AE_Candidate
Depressive I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
Pediatrics O
( O
6 O
-17 O
years O
) O
The O
overall O
profile O
of O
adverse O
reactions O
in O
pediatric O
patients O
was O
generally O
similar O
to O
that O
seen O
in O
adult O
studies O
, O
as O
shown O
in O
Table O
2 O
. O

However O
, O
the O
following O
adverse O
reactions O
( O
excluding O
those O
which O
appear O
in O
Table O
2 O
and O
those O
for O
which O
the O
coded O
terms O
were O
uninformative O
or O
misleading O
) O
were O
reported O
at O
an O
incidence O
of O
at O
least O
2 O
% O
for O
Lexapro O
and O
greater O
than O
placebo O
: O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
. O

Adults O
The O
most O
commonly O
observed O
adverse O
reactions O
in O
Lexapro O
patients O
( O
incidence O
of O
approximately O
5 O
% O
or O
greater O
and O
approximately O
twice O
the O
incidence O
in O
placebo O
patients O
) O
were O
insomnia B-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
) O
, O
nausea B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
. O

Table O
2 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
treatment-emergent O
adverse O
events O
that O
occurred O
among O
715 O
depressed B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
at O
doses O
ranging O
from O
10 O
to O
20 O
mg/day O
in O
placebo-controlled O
trials O
. O

Events O
included O
are O
those O
occurring O
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
Lexapro O
and O
for O
which O
the O
incidence O
in O
patients O
treated O
with O
Lexapro O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

TABLE O
2 O
Treatment-Emergent O
Adverse O
Reactions O
observed O
with O
a O
frequency O
of O
> O
= O
2 O
% O
and O
greater O
than O
placebo O
for O
Major O
Depressive O
Disorder O
1Primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
. O

2Denominator O
used O
was O
for O
males O
only O
( O
N=225 O
Lexapro O
; O
N=188 O
placebo O
) O
. O

3Denominator O
used O
was O
for O
females O
only O
( O
N=490 O
Lexapro O
; O
N=404 O
placebo O
) O
. O

Adverse O
Reaction O
Lexapro O
Placebo O
( O
N=715 O
) O
% O
( O
N=592 O
) O
% O
Autonomic B-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
6 O
% O
5 O
% O
Sweating B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
5 O
% O
2 O
% O
Central B-NonOSE_AE
& I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
5 O
% O
3 O
% O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
15 O
% O
7 O
% O
Diarrhea B-OSE_Labeled_AE
8 O
% O
5 O
% O
Constipation B-OSE_Labeled_AE
3 O
% O
1 O
% O
Indigestion B-OSE_Labeled_AE
3 O
% O
1 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
1 O
% O
General B-NonOSE_AE
Influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
5 O
% O
4 O
% O
Fatigue B-OSE_Labeled_AE
5 O
% O
2 O
% O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
9 O
% O
4 O
% O
Somnolence B-OSE_Labeled_AE
6 O
% O
2 O
% O
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Rhinitis B-OSE_Labeled_AE
5 O
% O
4 O
% O
Sinusitis B-OSE_Labeled_AE
3 O
% O
2 O
% O
Urogenital B-NonOSE_AE
Ejaculation B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
1,2 O
9 O
% O
< O
1 O
% O
Impotence B-OSE_Labeled_AE
2 O
3 O
% O
< O
1 O
% O
Anorgasmia B-OSE_Labeled_AE
3 O
2 O
% O
< O
1 O
% O
Generalized O
Anxiety O
Disorder O
Adults O
The O
most O
commonly O
observed O
adverse O
reactions O
in O
Lexapro O
patients O
( O
incidence O
of O
approximately O
5 O
% O
or O
greater O
and O
approximately O
twice O
the O
incidence O
in O
placebo O
patients O
) O
were O
nausea B-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
) O
, O
insomnia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
and O
anorgasmia B-OSE_Labeled_AE
. O

Table O
3 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
of O
treatment-emergent O
adverse O
events O
that O
occurred O
among O
429 O
GAD B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
10 O
to O
20 O
mg/day O
in O
placebo-controlled O
trials O
. O

Events O
included O
are O
those O
occurring O
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
Lexapro O
and O
for O
which O
the O
incidence O
in O
patients O
treated O
with O
Lexapro O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

TABLE O
3 O
Treatment-Emergent O
Adverse O
Reactions O
observed O
with O
a O
frequency O
of O
> O
= O
2 O
% O
and O
greater O
than O
placebo O
for O
Generalized O
Anxiety O
Disorder O
1Primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
. O

2Denominator O
used O
was O
for O
males O
only O
( O
N=182 O
Lexapro O
; O
N=195 O
placebo O
) O
. O

3Denominator O
used O
was O
for O
females O
only O
( O
N=247 O
Lexapro O
; O
N=232 O
placebo O
) O
. O

Adverse O
Reactions O
Lexapro O
Placebo O
( O
N=429 O
) O
% O
( O
N=427 O
) O
% O
Autonomic B-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
9 O
% O
5 O
% O
Sweating B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
4 O
% O
1 O
% O
Central B-NonOSE_AE
& I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
24 O
% O
17 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
18 O
% O
8 O
% O
Diarrhea B-OSE_Labeled_AE
8 O
% O
6 O
% O
Constipation B-OSE_Labeled_AE
5 O
% O
4 O
% O
Indigestion B-OSE_Labeled_AE
3 O
% O
2 O
% O
Vomiting B-OSE_Labeled_AE
3 O
% O
1 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
1 O
% O
Flatulence B-OSE_Labeled_AE
2 O
% O
1 O
% O
Toothache B-OSE_Labeled_AE
2 O
% O
0 O
% O
General B-NonOSE_AE
Fatigue B-OSE_Labeled_AE
8 O
% O
2 O
% O
Influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
5 O
% O
4 O
% O
Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
Disorder I-NonOSE_AE
Neck B-OSE_Labeled_AE
/Shoulder O
Pain I-OSE_Labeled_AE
3 O
% O
1 O
% O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
13 O
% O
7 O
% O
Insomnia B-OSE_Labeled_AE
12 O
% O
6 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
7 O
% O
2 O
% O
Dreaming B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
3 O
% O
2 O
% O
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Lethargy B-OSE_Labeled_AE
3 O
% O
1 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Yawning B-OSE_Labeled_AE
2 O
% O
1 O
% O
Urogenital B-NonOSE_AE
Ejaculation B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
1,2 O
14 O
% O
2 O
% O
Anorgasmia B-OSE_Labeled_AE
3 O
6 O
% O
< O
1 O
% O
Menstrual B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
2 O
% O
1 O
% O
Dose O
Dependency O
of O
Adverse O
Reactions O
The O
potential O
dose O
dependency O
of O
common O
adverse O
reactions O
( O
defined O
as O
an O
incidence O
rate O
of O
> O
=5 O
% O
in O
either O
the O
10 O
mg O
or O
20 O
mg O
Lexapro O
groups O
) O
was O
examined O
on O
the O
basis O
of O
the O
combined O
incidence O
of O
adverse O
reactions O
in O
two O
fixed-dose O
trials O
. O

The O
overall O
incidence O
rates O
of O
adverse O
events O
in O
10 O
mg O
Lexapro-treated O
patients O
( O
66 O
% O
) O
was O
similar O
to O
that O
of O
the O
placebo-treated O
patients O
( O
61 O
% O
) O
, O
while O
the O
incidence O
rate O
in O
20 O
mg/day O
Lexapro-treated O
patients O
was O
greater O
( O
86 O
% O
) O
. O

Table O
4 O
shows O
common O
adverse O
reactions O
that O
occurred O
in O
the O
20 O
mg/day O
Lexapro O
group O
with O
an O
incidence O
that O
was O
approximately O
twice O
that O
of O
the O
10 O
mg/day O
Lexapro O
group O
and O
approximately O
twice O
that O
of O
the O
placebo O
group O
. O

TABLE O
4 O
Incidence O
of O
Common O
Adverse O
Reactions O
in O
Patients O
with O
Major O
Depressive O
Disorder O
Adverse O
Reaction O
Placebo O
10 O
mg/day O
20 O
mg/day O
( O
N=311 O
) O
Lexapro O
Lexapro O
( O
N=310 O
) O
( O
N=125 O
) O
Insomnia B-OSE_Labeled_AE
4 O
% O
7 O
% O
14 O
% O
Diarrhea B-OSE_Labeled_AE
5 O
% O
6 O
% O
14 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
3 O
% O
4 O
% O
9 O
% O
Somnolence B-OSE_Labeled_AE
1 O
% O
4 O
% O
9 O
% O
Dizziness B-OSE_Labeled_AE
2 O
% O
4 O
% O
7 O
% O
Sweating B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
< O
1 O
% O
3 O
% O
8 O
% O
Constipation B-OSE_Labeled_AE
1 O
% O
3 O
% O
6 O
% O
Fatigue B-OSE_Labeled_AE
2 O
% O
2 O
% O
6 O
% O
Indigestion B-OSE_Labeled_AE
1 O
% O
2 O
% O
6 O
% O
Male O
and O
Female O
Sexual O
Dysfunction O
with O
SSRIs O
Although O
changes B-NonOSE_AE
in I-NonOSE_AE
sexual I-NonOSE_AE
desire I-NonOSE_AE
, O
sexual B-NonOSE_AE
performance I-NonOSE_AE
, O
and O
sexual B-NonOSE_AE
satisfaction I-NonOSE_AE
often O
occur O
as O
manifestations O
of O
a O
psychiatric B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
they O
may O
also O
be O
a O
consequence O
of O
pharmacologic O
treatment O
. O

In O
particular O
, O
some O
evidence O
suggests O
that O
SSRIs O
can O
cause O
such O
untoward B-OSE_Labeled_AE
sexual I-OSE_Labeled_AE
experiences I-OSE_Labeled_AE
. O

Reliable O
estimates O
of O
the O
incidence O
and O
severity O
of O
untoward B-NonOSE_AE
experiences I-NonOSE_AE
involving I-NonOSE_AE
sexual I-NonOSE_AE
desire O
, O
performance O
, O
and O
satisfaction I-NonOSE_AE
are O
difficult O
to O
obtain O
, O
however O
, O
in O
part O
because O
patients O
and O
physicians O
may O
be O
reluctant O
to O
discuss O
them O
. O

Accordingly O
, O
estimates O
of O
the O
incidence O
of O
untoward B-NonOSE_AE
sexual I-NonOSE_AE
experience O
and O
performance I-NonOSE_AE
cited O
in O
product O
labeling O
are O
likely O
to O
underestimate O
their O
actual O
incidence O
. O

TABLE O
5 O
Incidence O
of O
Sexual O
Side O
Effects O
in O
Placebo-Controlled O
Clinical O
Trials O
Adverse O
Event O
Lexapro O
Placebo O
In O
Males O
Only O
( O
N=407 O
) O
( O
N=383 O
) O
Ejaculation B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
( O
primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
) O
12 O
% O
1 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
6 O
% O
2 O
% O
Impotence B-OSE_Labeled_AE
2 O
% O
< O
1 O
% O
In O
Females O
Only O
( O
N=737 O
) O
( O
N=636 O
) O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Anorgasmia B-OSE_Labeled_AE
3 O
% O
< O
1 O
% O
There O
are O
no O
adequately O
designed O
studies O
examining O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
with O
escitalopram O
treatment O
. O

Priapism B-OSE_Labeled_AE
has O
been O
reported O
with O
all O
SSRIs O
. O

While O
it O
is O
difficult O
to O
know O
the O
precise O
risk O
of O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
associated O
with O
the O
use O
of O
SSRIs O
, O
physicians O
should O
routinely O
inquire O
about O
such O
possible O
side O
effects O
. O

Vital O
Sign O
Changes O
Lexapro O
and O
placebo O
groups O
were O
compared O
with O
respect O
to O
( O
1 O
) O
mean O
change O
from O
baseline O
in O
vital O
signs O
( O
pulse O
, O
systolic O
blood O
pressure O
, O
and O
diastolic O
blood O
pressure O
) O
and O
( O
2 O
) O
the O
incidence O
of O
patients O
meeting O
criteria O
for O
potentially O
clinically O
significant O
changes O
from O
baseline O
in O
these O
variables O
. O

These O
analyses O
did O
not O
reveal O
any O
clinically O
important O
changes O
in O
vital O
signs O
associated O
with O
Lexapro O
treatment O
. O

In O
addition O
, O
a O
comparison O
of O
supine O
and O
standing O
vital O
sign O
measures O
in O
subjects O
receiving O
Lexapro O
indicated O
that O
Lexapro O
treatment O
is O
not O
associated O
with O
orthostatic B-NonOSE_AE
changes I-NonOSE_AE
. O

Weight O
Changes O
Patients O
treated O
with O
Lexapro O
in O
controlled O
trials O
did O
not O
differ O
from O
placebo-treated O
patients O
with O
regard O
to O
clinically O
important O
change B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
. O

Laboratory O
Changes O
Lexapro O
and O
placebo O
groups O
were O
compared O
with O
respect O
to O
( O
1 O
) O
mean O
change O
from O
baseline O
in O
various O
serum O
chemistry O
, O
hematology O
, O
and O
urinalysis O
variables O
, O
and O
( O
2 O
) O
the O
incidence O
of O
patients O
meeting O
criteria O
for O
potentially O
clinically O
significant O
changes O
from O
baseline O
in O
these O
variables O
. O

These O
analyses O
revealed O
no O
clinically O
important O
changes B-NonOSE_AE
in I-NonOSE_AE
laboratory I-NonOSE_AE
test I-NonOSE_AE
parameters O
associated O
with O
Lexapro O
treatment O
. O

ECG B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
Electrocardiograms O
from O
Lexapro O
( O
N=625 O
) O
and O
placebo O
( O
N=527 O
) O
groups O
were O
compared O
with O
respect O
to O
outliers O
defined O
as O
subjects O
with O
QTc B-NonOSE_AE
changes I-NonOSE_AE
over I-NonOSE_AE
6 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
or O
absolute O
values O
over O
500 O
msec O
post-dose O
, O
and O
subjects O
with O
heart B-NonOSE_AE
rate I-NonOSE_AE
increases I-NonOSE_AE
to O
over O
100 O
bpm O
or O
decreases O
to O
less O
than O
50 O
bpm O
with O
a O
25 O
% O
change O
from O
baseline O
( O
tachycardic B-NonOSE_AE
or O
bradycardic B-NonOSE_AE
outliers O
, O
respectively O
) O
. O

None O
of O
the O
patients O
in O
the O
Lexapro O
group O
had O
a O
QTcF B-NonOSE_AE
interval I-NonOSE_AE
> I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
or O
a O
prolongation O
> O
60 O
msec O
compared O
to O
0.2 O
% O
of O
patients O
in O
the O
placebo O
group O
. O

The O
incidence O
of O
tachycardic B-NonOSE_AE
outliers O
was O
0.2 O
% O
in O
the O
Lexapro O
and O
the O
placebo O
group O
. O

The O
incidence O
of O
bradycardic B-OSE_Labeled_AE
outliers O
was O
0.5 O
% O
in O
the O
Lexapro O
group O
and O
0.2 O
% O
in O
the O
placebo O
group O
. O

QTcF O
interval O
was O
evaluated O
in O
a O
randomized O
, O
placebo O
and O
active O
( O
moxifloxacin O
400 O
mg O
) O
controlled O
cross-over O
, O
escalating O
multiple-dose O
study O
in O
113 O
healthy O
subjects O
. O

The O
maximum O
mean O
( O
95 O
% O
upper O
confidence O
bound O
) O
difference O
from O
placebo O
arm O
were O
4.5 O
( O
6.4 O
) O
and O
10.7 O
( O
12.7 O
) O
msec O
for O
10 O
mg O
and O
supratherapeutic O
30 O
mg O
escitalopram O
given O
once O
daily O
, O
respectively O
. O

Based O
on O
the O
established O
exposure-response O
relationship O
, O
the O
predicted B-OSE_Labeled_AE
QTcF I-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
placebo I-OSE_Labeled_AE
arm I-OSE_Labeled_AE
( I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
confidence I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
) I-OSE_Labeled_AE
under I-OSE_Labeled_AE
the I-OSE_Labeled_AE
Cmaxfor I-OSE_Labeled_AE
the I-OSE_Labeled_AE
dose I-OSE_Labeled_AE
of I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
is I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
( I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
) I-OSE_Labeled_AE
msec I-OSE_Labeled_AE
. O

Escitalopram O
30 O
mg O
given O
once O
daily O
resulted O
in O
mean O
Cmaxof O
1.7-fold O
higher O
than O
the O
mean O
Cmaxfor O
the O
maximum O
recommended O
therapeutic O
dose O
at O
steady O
state O
( O
20 O
mg O
) O
. O

The O
exposure O
under O
supratherapeutic O
30 O
mg O
dose O
is O
similar O
to O
the O
steady O
state O
concentrations O
expected O
in O
CYP2C19 O
poor O
metabolizers O
following O
a O
therapeutic O
dose O
of O
20 O
mg O
. O
Other O
Reactions O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
Lexapro O
Following O
is O
a O
list O
of O
treatment-emergent O
adverse O
events O
, O
as O
defined O
in O
the O
introduction O
to O
the O
ADVERSE O
REACTIONS O
section O
, O
reported O
by O
the O
1428 O
patients O
treated O
with O
Lexapro O
for O
periods O
of O
up O
to O
one O
year O
in O
double-blind O
or O
open-label O
clinical O
trials O
during O
its O
premarketing O
evaluation O
. O

The O
listing O
does O
not O
include O
those O
events O
already O
listed O
in O
Tables O
2 O
& O
3 O
, O
those O
events O
for O
which O
a O
drug O
cause O
was O
remote O
and O
at O
a O
rate O
less O
than O
1 O
% O
or O
lower O
than O
placebo O
, O
those O
events O
which O
were O
so O
general O
as O
to O
be O
uninformative O
, O
and O
those O
events O
reported O
only O
once O
which O
did O
not O
have O
a O
substantial O
probability O
of O
being O
acutely O
life O
threatening O
. O

Events O
are O
categorized O
by O
body O
system O
. O

Events O
of O
major O
clinical O
importance O
are O
described O
in O
the O
Warnings O
and O
Precautions O
section O
( O
5 O
) O
. O

Cardiovascular B-NonOSE_AE
- O
hypertension B-OSE_Labeled_AE
, O
palpitation B-OSE_Labeled_AE
. O

Central B-NonOSE_AE
and I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
light B-OSE_Labeled_AE
- I-OSE_Labeled_AE
headed I-OSE_Labeled_AE
feeling I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
- O
abdominal B-OSE_Labeled_AE
cramp I-OSE_Labeled_AE
, O
heartburn B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
. O

General B-NonOSE_AE
- O
allergy B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
limb I-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
- O
increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
arthralgia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
jaw B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
- O
appetite B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
concentration B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
Disorders I-NonOSE_AE
/ I-NonOSE_AE
Female I-NonOSE_AE
- O
menstrual B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
menstrual B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
bronchitis B-OSE_Labeled_AE
, O
coughing B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Disorders I-NonOSE_AE
- O
rash B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
- O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
. O

Urinary B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

6.2 O
Post-Marketing O
Experience O
Adverse O
Reactions O
Reported O
Subsequent O
to O
the O
Marketing O
of O
Escitalopram O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
from O
spontaneous O
reports O
of O
escitalopram O
received O
worldwide O
. O

These O
adverse O
reactions O
have O
been O
chosen O
for O
inclusion O
because O
of O
a O
combination O
of O
seriousness O
, O
frequency O
of O
reporting O
, O
or O
potential O
causal O
connection O
to O
escitalopram O
and O
have O
not O
been O
listed O
elsewhere O
in O
labeling O
. O

However O
, O
because O
these O
adverse O
reactions O
were O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
events O
include O
: O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
agranulocytis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
idiopathic B-OSE_Labeled_AE
thrombocytopenia I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
: O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
hyperprolactinemia B-OSE_Labeled_AE
, O
SIADH B-OSE_Labeled_AE
. O

Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorder I-NonOSE_AE
: O
dysphagia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
fall B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
. O

Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
: O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
anaphylaxis B-OSE_Labeled_AE
. O

Investigations B-NonOSE_AE
: O
bilirubin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
INR B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
prothrombin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
: O
hyperglycemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
muscle B-OSE_Labeled_AE
cramp I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
rhabdomyolysis B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
akathisia B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
choreoathetosis B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
seizures I-OSE_Labeled_AE
( O
or O
convulsions B-OSE_Labeled_AE
) O
, O
hypoaesthesia B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
Parkinsonism B-OSE_Labeled_AE
, O
restless B-OSE_Labeled_AE
legs I-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
. O

Pregnancy B-NonOSE_AE
, I-NonOSE_AE
Puerperium I-NonOSE_AE
and I-NonOSE_AE
Perinatal I-NonOSE_AE
Conditions I-NonOSE_AE
: O
spontaneous B-OSE_Labeled_AE
abortion I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
psychosis I-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
anger B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
completed B-OSE_Labeled_AE
suicide I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
aggravated I-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
delusion B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
unreal I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
( I-OSE_Labeled_AE
visual O
and O
auditory I-OSE_Labeled_AE
) O
, O
mood B-OSE_Labeled_AE
swings I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
nightmare B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
paranoia B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
self B-OSE_Labeled_AE
- I-OSE_Labeled_AE
harm I-OSE_Labeled_AE
or O
thoughts B-OSE_Labeled_AE
of I-OSE_Labeled_AE
self I-OSE_Labeled_AE
- I-OSE_Labeled_AE
harm I-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
attempt I-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
tendency I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
menorrhagia B-OSE_Labeled_AE
, O
priapism B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
: O
dyspnea B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
newborn I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
alopecia B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
. O

Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
. O

